SLSile Li

Sile Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sile Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Asif Rashid

    Department of Paediatrics and Adolescent Medicine Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong Hong Kong SAR P. R. China

    1 shared publication
  • Chichao Xia

    Department of Microbiology The Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong SAR China

    1 shared publication
  • Hong Kee Tan

    Cancer Science Institute of Singapore, Singapore, Singapore

    1 shared publication
  • Kee See Lam

    Department of Paediatrics and Adolescent Medicine Hong Kong Children's Hospital Kowloon Hong Kong SAR P. R. China

    1 shared publication
  • Man Yan Hui

    Department of Paediatrics and Adolescent Medicine Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong Hong Kong SAR P. R. China

    1 shared publication
  • Paul Kay Sheung Chan

    Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China

    1 shared publication

Latest Publications

  • Open Access

    Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

    by Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, et al.

    The use of chimeric antigen receptor (CAR) T‐cell therapy for T‐cell malignancies is limited by fratricide, antigen‐escape, lack of functional endurance and adverse events such as multilineage cytopenia. To address these limitations, we developed a simple single‐step CD7‐depletion process followed by transduction with a lentiviral vector encoding a CCR4/CD7 bispecific CAR. CD7‐negative (CD7N) CCR4/CD7 CAR‐T cells could expand without experiencing fratricide, unlike the bulk CCR4/CD7 CAR‐T cells. The CD7N CAR‐T exhibited robust cytotoxicity against malignant T‐cell lines with heterogeneous CD7 and CCR4 expression in vitro and in vivo. Incorporation of EGFRt in the CAR construct allowed elimination by cetuximab in case of adverse events, whereas inclusion of c‐Jun in the construct reduced functional exhaustion after repeated tumor challenges in vitro. In comparison to non‐transduced CD7N cells and Bulk CAR‐T cells, scRNA‐seq analysis of CD7N CAR‐T cells revealed a unique AQP3+ CD4+ T‐cell subset following exposure to tumor cells. This cell subset exhibited broad activation of the Src/Ras/ERK and Bcl‐2 pathways, high levels of SOS1 and KLF2 expression, and specific ligand‐receptor interactions within the tumor necrosis factor superfamily. Collectively, these results suggest that further clinical development of CCR4/CD7 bispecific CD7N CAR‐T cells is warranted, including the AQP3+ subset with SOS1 / KLF2 modulation.


  • Open Access

    Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia

    by Chichao Xia, Sile Li, Teng Long, Zigui Chen, Paul K. S. Chan, Siaw Shi Boon

    Human papillomavirus (HPV) infection remains one of the most prominent cancer-causing DNA viruses, contributing to approximately 5% of human cancers. While association between HPV and cervical cancers has been well-established, evidence on the attribution of head and neck cancers (HNC) to HPV have been increasing in recent years. Among the cancer-causing HPV genotypes, HPV16 and 18 remain the major contributors to cancers across the globe. Nonetheless, the distribution of HPV genotypes in ethnically, geographically, and socio-economically diverse East, Southeast, and South Asia may differ from other parts of the world. In this review, we garner and provide updated insight into various aspects of HPV reported in recent years (2015–2021) in these regions. We included: (i) the HPV genotypes detected in normal cancers of the uterine cervix and head and neck, as well as the distribution of the HPV genotypes by geography and age groups; (ii) the laboratory diagnostic methods and treatment regimens used within these regions; and (iii) the oncogenic properties of HPV prototypes and their variants contributing to carcinogenesis. More importantly, we also unveil the similarities and discrepancies between these aspects, the areas lacking study, and the challenges faced in HPV studies.